Imaging in thyroid-associated orbitopathy

European Journal of Endocrinology

Volumn 145, Issue 2, 2001, Pages 107-118

  Kahaly, G J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

AUTOIMMUNE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOCRINE OPHTHALMOPATHY; EXTRAOCULAR MUSCLE; GRAVES DISEASE; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY;

EID: 0034906422     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1450107     Document Type: Review

References (95)

1. Management of Graves' ophthalmopathy: Reality and perspectives
2. Medical progress: Graves' disease
3. Assessment of disease activity of Graves' ophthalmopathy
4. Graves' ophthalmopathy
5. Natural history of thyroid eye disease
6. Clinical presentation of thyroid-associated orbitopathy
7. Retrobulbar histology and immunohistochemistry in endocrine ophthalmopathy
8. Diagnostic criteria for Graves' ophthalmopathy
9. Pathogenesis and pathophysiology of thyroid ophthalmopathy
10. Longterm observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures
11. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
12. Pathogenesis of Graves' ophthalmopathy
13. Retro-orbital autoimmunity
14. Thyroid-associated ophthalmopathy - A model for the association of organ-specific autoimmune disorders
15. Elephantiasic pretibial myxedema: Insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease
16. Orbital pathology in Graves' disease
17. Immunohistochemical staining of retrobulbar adipose tissue in Graves' ophthalmopathy
18. Autoimmune endocrine ophthalmopathy and retrobulbar antigens
19. TSH receptor in endocrine autoimmunity
20. Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens
21. T cells and orbital connective tissue in endocrine orbitopathy
22. Analysis of orbital T cells in thyroid-associated ophthalmopathy
23. Cytokines in the evolution of Graves' ophthalmopathy
24. Urinary glycosaminoglycans in Graves' ophthalmopathy
25. Glycosaminoglycans in autoimmunity
26. HPLC glycosaminoglycan analysis in patients with Graves' disease
27. Glycosaminoglycans in thyroid eye disease
28. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy
29. Ocular changes in Graves' disease. A long-term follow-up study
30. Pathologic changes in the orbit in progressive exophthalmos
31. Immunohistochemical staining of normal and Graves' extraocular muscle
32. Ciclosporin and prednisone vs prednisone in treatment of Graves' ophthalmopathy: A controlled, randomized and prospective study
33. Randomized trial of intravenous immunoglobulins vs prednisolone in Graves' ophthalmopathy
34. Radiotherapy for thyroid-associated orbitopathy
35. Low vs high-dose radiotherapy for Graves' ophthalmopathy: A randomized, single-blind trial
36. Radiotherapy for Graves' ophthalmopathy
37. Orbital decompression for endocrine ophthalmopathy: The endonasal approach
38. Decompression surgery for thyroid-associated orbitopathy - A ten year experience
39. New imaging procedures in thyroid-associated ophthalmopathy
40. CT characteristics of orbital pseudotumor and other orbital inflammatory processes
41. The measurement of change in Graves' ophthalmopathy
42. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey
43. Graves' orbitopathy
44. Neuroradiological diagnosis of thyroid-associated orbitopathy
45. Correlation of CT scanning and pathologic features of opthalmic Graves' disease
46. Dysthyroid optic neuropathy
47. Graves' orbitopathy: Correlation of CT and clinical findings
48. Computer analysis of orbital fat and muscle volumes in Graves' ophthalmopathy
49. Volume measurements of normal orbital structures by computed tomographic analysis
50. Ophthalmopathy of Graves' disease: Computerized volume measurements of orbital fat and muscle
51. Appearance of Graves' disease on orbital computed tomography
52. Role of rectus muscle enlargement in clinical profile of dysthyroid ophthalmopathy
53. Optic nerve dysfunction in thyroid eye disease: CT
54. Quantitative computer tomography of Graves' ophthalmopathy
55. Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography
56. Graves' ophthalmopathy: MR imaging of the orbits
57. Graves' ophthalmopathy: Role of MR imaging in radiation therapy
58. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: Its predictive value for therapeutic outcome of immunosuppressive therapy
59. MR relaxation time measurements with and without selective fat suppression (SPIR) in endocrine orbitopathy
60. Correlation between computed tomography and magnetic resonance imaging in Graves' orbitopathy
61. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid stimulating antibody in patients with Graves' ophthalmopathy
62. Extraocular muscles in Graves' ophthalmopathy: Usefulness of T2 relaxation time measurements
63. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy
64. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy
65. Ultrasonographic evidence of a consistant orbital involvement in Graves' disease
66. Ultrasonic B scan measurement of the extraocular muscles in Graves' orbitopathy
67. Extraocular muscle size comparison using standardized A-scan echography and computed tomography scan measurements
68. B-scan ultrasonography in Graves' orbitopathy
69. Diameter of normal extraocular muscles with echography
70. The use of real/time orbital ultrasound in Graves' ophthalmopathy: A comparison with computer tomography
71. Echographic monitoring of response of extraocular muscles to irradiation in Graves' ophthalmopathy
72. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy
73. Graves' ophthalmopathy: Eye muscle involvement in patients with diplopia
74. Comparison of standardized echography with magnetic resonance imaging to measure extraocular muscle size
75. Color Doppler ultrasound findings in patients with thyroid ophthalmopathy
76. Somatostatin receptor scintigraphy with [111-In-DTPA-D-Phe1]-octreotide in man: Metabolism, dosimetry, and comparison with [123-I-Tyr-3]-octreotide
77. Somatostatin receptor scintigraphy with [111-In-DTAP-D-Phe1] and [123 I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients
78. Somatostatin receptor scintigraphy
79. The role of octreoscan in thyroid eye disease
80. Octreotide scintigraphy in thyroidal and orbital Graves' disease
81. Somatostatin receptors in the orbit
82. 111-In-Octreotide imaging in patients with longstanding Graves' ophthalmopathy
83. Octreoscan in Graves' ophthalmopathy
84. Somatostatin-receptor scintigraphy in Graves' disease: Reproducibility and inter-/intra-observer variability
85. Somatostatin-receptor scintigraphy in Graves' ophthalmopathy. A new, standardized method for assessment of orbital disease activity
86. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy
87. Indium-111-pentetreotide in Graves' disease
88. Somatostatin receptor scintigraphy in thyroid eye disease
89. [111-In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?
90. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy
91. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using somatostatin analog 111-In-octreotide
92. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease
93. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease
94. Lanreotide in the treatment of patients with thyroid eye disease